+13.1%
GSK vs ZYBT
-42.3%
+55.4%
-22.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | ZYBT | Excess | Alpha |
|---|---|---|---|---|
| 1D | +5.0% | +2.2% | +2.8% | +5.0% |
| 7D | +4.9% | -3.5% | +8.5% | +4.9% |
| 30D | +9.9% | +15.1% | -5.2% | +10.0% |
| 3M | +0.2% | +7.0% | -6.9% | +0.3% |
| 6M | +2.3% | +37.7% | -35.4% | +5.6% |
| YTD | +7.1% | +19.1% | -12.1% | +12.1% |
| 1Y | +13.1% | -38.3% | +51.4% | +19.9% |
| All | +13.1% | -42.3% | +55.4% | +19.9% |
Cumulative growth
Daily Returns
Daily percentage return beside ZYBT.
Daily Out/Under-Performance
Portfolio return minus ZYBT return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × ZYBT return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded ZYBT wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling